Impact of CYP2C19 Metabolizer Status on Patients With ACS Treated With Prasugrel Versus Clopidogrel - Doll, Jacob A.; Neely, Megan L.; Roe, Matthew T.; Armstrong, Paul W.; White, Harvey D.; Prabhakaran, Dorairaj; Winters, Kenneth J.; Duvvuru, Suman; Sundseth, Scott S.; Jakubowski, Joseph A.; Gurbel, Paul A.; Bhatt, Deepak L.; et al. (Journal of the American College of Cardiology, 2016)
Keywords: acute coronary syndrome; Acute Coronary Syndrome - blood; Acute Coronary Syndrome - drug therapy; Acute Coronary Syndrome - genetics; Acute coronary syndromes; Aged; Alleles; Angina pectoris; Blood platelets; Cardiology; Cardiovascular; Cardiovascular disease; Clinical outcomes; Confidence intervals; Coronary vessels; Cytochrome P-450 CYP2C19 - genetics; Cytochrome P-450 CYP2C19 - metabolism; Deoxyribonucleic acid; DNA; DNA - genetics; Dose-Response Relationship, Drug; Double-Blind Method; Drug dosages; dual antiplatelet therapy; Enzymes; Female; Follow-Up Studies; Genetics; Genotype; Genotype & phenotype; Heart attacks; Humans; Male; Metabolism; Metabolites; Middle Aged; Platelet Aggregation Inhibitors - administration & dosage; Platelet Function Tests; platelets; Polymorphism, Genetic; Prasugrel Hydrochloride - administration & dosage; Purinergic P2Y Receptor Antagonists - administration & dosage; Retrospective Studies; Stroke; Ticlopidine - administration & dosage; Ticlopidine - analogs & derivatives; Treatment Outcome; United States--US; California; NSTEMI; FDA; CI; EM; HR; UA; platelets; dual antiplatelet therapy; ACS; PRU; acute coronary syndrome; genetics; PCI; CYP; RM; MI; myocardial infarction; P2Y 12 reaction unit; percutaneous coronary intervention; extensive metabolizer(s); non–ST-segment elevation myocardial infarction; U.S. Food and Drug Administration; cytochrome P450; reduced metabolizer(s); hazard ratio; confidence interval; unstable angina